Agree as per usual FMF but POH must focus everything they have on the most likely short term gain rather than multiple opportunities. IMO, if there's one thing POH should have learned from this experience, its not to spread resources to thin chasing multiple opportunities. Particularly a small company like POH. Also, funding could come from outside the stock market process particularly if the FDA meeting has gone well. A C/R is not the only option. GLTA
- Forums
- ASX - By Stock
- Ann: Phosphagenics and Mylan Agree Settlement
Agree as per usual FMF but POH must focus everything they have...
-
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add POH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.0¢ |
Change
0.000(0.00%) |
Mkt cap ! n/a |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
POH (ASX) Chart |
Day chart unavailable